Antibodies under a microscope

DHC13102

Research Grade Rovelizumab

Description

Bispecific, Hu23F2G, 23F2G, CAS: 339086-79-2

Targets

Complement receptor C3 subunit beta, Cell surface adhesion glycoproteins LFA-1/CR3/p150, 95 subunit beta, Integrin beta-2, MFI7, CD18, ITGB2, CD11A, Leukocyte function-associated molecule 1 alpha chain, Leukocyte adhesion glycoprotein LFA-1 alpha chain, LFA-1A, CD11 antigen-like family member A, CD11a, ITGAL, Integrin alpha-L, CR-3 alpha chain, Cell surface glycoprotein MAC-1 subunit alpha, Leukocyte adhesion receptor MO1, ITGAM, CD11b, CD11 antigen-like family member B, Integrin alpha-M, CR3A, CD11B, Neutrophil adherence receptor

Isotype/Mimetic

IgG4-nd

Animal-Derived Biomaterials Used

None

Sequence Available

No

Original Discovery Method

Unknown

Original Discovery Information Provided On Datasheet

No

Antibody/Binder Origins

Unknown discovery source/method, In vitro recombinant expression